Prostate cancer breakthrough: New drug could extend life of patients by ‘two years’

Prostate cancer breakthrough: New drug could extend life of patients by 'two years' - study
Prostate cancer breakthrough: New drug could extend life of patients by 'two years' - study

Prostate cancer breakthrough: New drug could extend life of patients by ‘two years’

Prostate cancer breakthrough: New drug could extend life of patients by ‘two years’ – study.

Researchers found some men, who exhausted all other options, were alive and well even after a clinical trial ended.

Prostate cancer breakthrough: New drug could extend life of patients by 'two years' - study

The so-called ‘super responders’ reacted to the humanised antibody pembrolizumab. File pic

Some men with advanced prostate cancer could survive for at least two more years on immunotherapy, according to a new study.

Researchers discovered a small proportion of men – one in 20 – who exhausted all other options, were alive and well, even after a clinical trial ended.

The so-called “super responders” in the later stages of the condition, reacted to the humanised antibody pembrolizumab.
Prostate cancer breakthrough: New drug could extend life of patients by 'two years' - study
Researchers found one-in-20 men were alive and well, even after a clinical trial ended. File pic

The study, published in the Journal of Clinical Oncology, said the most dramatic responses were seen in patients whose tumours had mutations in genes involved in repairing DNA.

Scientists are now looking at whether this group might especially benefit from immunotherapy, which is a type of treatment that uses the body’s immune system to fight cancer by recognising and attacking cancer cells.

Share this post

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.


%d bloggers like this: